ArticleCancers2023

Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL.

Anne Rogiers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.